Entasis Therapeutics

Focused on the discovery and development of novel antibacterial products

A spin-out from AstraZeneca, Entasis Therapeutics is developing a portfolio of innovative product candidates to treat serious Gram-negative multi-drug resistant bacterial infections. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections.

Status

IPO in 2018 (NASDAQ: ETTX)

Year of Investment

2016

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Waltham, Massachusetts